Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 230889th Legislature (2025)

What changed between versions

320 paragraphs changed+1493 words added−813 removed

Highlighted text was added in the newer version. Struck-through text was removed.

89R28276 CJD-F

By: Parker, et al.

S.B. No. 2308

(Harris, Leach, Phelan, Orr, VanDeaver, et al.)

Substitute the following for S.B. No. 2308: No.

A BILL TO BE ENTITLED

AN ACT

relating to the establishment of a grant programconsortium to fund theconduct United

States Food and Drug Administration's drug development trials withclinical

trials with ibogaine forto the purpose of securingsecure the administration's approval of the

asmedication's a medicationuse for treatment of opioid use disorder, co-occurring

substance use disorder, and any other neurological or mental health

conditions for which ibogaine demonstrates efficacy. and to the

administration of that treatment.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. Subtitle C, Title 6, Health and Safety Code, is

amended by adding Chapter 491 to read as follows:

CHAPTER 491. GRANTIBOGAINE PROGRAM FOR DRUG DEVELOPMENT OF IBOGAINETREATMENT

TREATMENT

SUBCHAPTER A. GENERAL PROVISIONS

Sec. 491.001. DEFINITIONS. In this chapter:

(1) "Commission" means the Health and Human Services

Commission.

(2) "Executive commissionerComptroller" means the executivecomptroller of public

commissioner of the Health and Human Services Commission.

Sec. 491.002. RULES. The executive commissioner shall

adopt rules necessary to administer this chapter.

Sec. 491.003. ESTABLISHMENT OF GRANT PROGRAM. The

commission shall establish and administer a grant program to fund a

public-private partnership program that will pay for the costs of

the United States Food and Drug Administration's drug development

trials with ibogaine to secure the administration's approval as a

medication for treatment of opioid use disorder, co-occurring

substance use disorder, and any other neurological or mental health

conditions for which ibogaine demonstrates efficacy.

Sec. 491.004. APPLICATION. (a) The commission shall

prepare and issue a notice of funding opportunity to solicit

applications for the grant program established under this chapter.

(b) An applicant may apply to the commission in the form and

manner prescribed by the commission for a grant under this chapter.

To be eligible for a grant, an applicant must:

(1) be a for-profit, nonprofit, or public benefit

corporate entity that has the requisite organizational and

financial capacity to:

(A) conduct the United States Food and Drug

accounts.

(3) "Drug developer" means a pharmaceutical company,

biotechnology company, or contract development and manufacturing

Administration'sorganization engaged in drug development trialsand with ibogaine to securemanufacturing.

the administration's approval as a medication for treatment of

opioid use disorder, co-occurring substance use disorder, and any

other neurological or mental health conditions for which ibogaine

demonstrates efficacy;

(B) as a result of the data obtained from the drug

development trial described by Paragraph (A), seek United States

Food and Drug Administration approval of ibogaine; and

(C) conduct future drug development trials of

ibogaine as a medication for treatment of opioid use disorder,

co-occurring substance use disorder, and any other neurological or

mental health conditions for which ibogaine demonstrates efficacy;

and

(2) provide:

(A) a detailed description of the planned

strategy for obtaining approval for the drug development trial from

(4) "Hospital" has the meaning assigned by Section

241.003.

(5) "Ibogaine" means ibogaine and ibogaine-based

therapeutics, including ibogaine analogs.

(6) "Institution of higher education" has the meaning

assigned by Section 61.003, Education Code.

SUBCHAPTER B. DRUG DEVELOPMENT OF IBOGAINE TREATMENT

Sec. 491.051. ESTABLISHMENT OF CONSORTIUM. (a) A

consortium may be established under this section and apply for

commission selection under this subchapter to conduct drug

development clinical trials with ibogaine and secure the United

States Food and Drug Administration's approval of ibogaine as a

medication for the treatment of:

(1) opioid use disorder;

(2) co-occurring substance use disorder; and

(3) any other neurological or mental health condition

for which ibogaine demonstrates efficacy.

(b) A consortium established under this section must

include one or more of each of the following entities:

(1) a drug developer;

(2) an institution of higher education; and

(3) a hospital.

Sec. 491.052. LEAD INSTITUTION; ADMINISTRATION; PERSONNEL.

(a) A consortium established under this subchapter shall select a

lead institution of higher education from among the consortium's

members to represent the consortium and perform administrative

functions under this subchapter, including contracting with and

reporting to the commission as required by this subchapter.

(b) A consortium selected by the commission under this

subchapter may employ personnel, including clinical,

administrative, and data management personnel, necessary to

support any consortium member's activities related to drug

development clinical trials conducted under this subchapter.

Sec. 491.053. CONSORTIUM PROPOSAL. (a) The lead

institution of higher education of a consortium shall submit to the

commission a proposal and request for funding on behalf of the

consortium for purposes of conducting ibogaine drug development

clinical trials in accordance with this subchapter.

(b) A proposal submitted under Subsection (a) must provide:

(1) the identity of all consortium members;

(2) a detailed description of the planned strategy for

obtaining approval for the drug development clinical trials from

the United States Food and Drug Administration;

(B3) a detailed drug development clinical trial design that

that includes:

(iA) a description of the composition of the

applicant'sconsortium's drug development clinical trial team and the expertise of the

of the team members;

(iiB) a drug development clinical trial participant

participant recruitment plan;

(iiiC) detailed patient screening criteria and cardiac

and cardiac safety protocols;

(ivD) administration protocols;

(vE) an aftercare and post-acute treatment

support plan; and

(viF) a data integrity plan;

(4) a detailed plan to seek a breakthrough therapy

designation for ibogaine from the United States Food and Drug

Administration under 21 U.S.C. Section 356;

(C5) a proposal to recognize this state's commercial

commercial interest in all patentable intellectual property that may be generated over

may be generated over the course of the drug development clinical trials, including:

including:

(iA) the treatment that is the subject of the

trials;

(iiB) administration protocols;

(iiiC) treatment models or techniques; and

(ivD) technology used in the trials;

(D6) a plan to establish a corporate presence in this

this state and to promote and maintain ibogaine-related biomedical

research, development, treatment, manufacturing, and distribution

in this state;

(E7) a plan to secure third-party payor approval for

for ibogaine treatment following approval by the United States Food and

and Drug Administration through:

(iA) private insurers;

(iiB) Medicare;

(iiiC) Medicaid; and

(ivD) the TRICARE program of the United States

States Department of Defense;

(F8) a plan to ensure ibogaine treatment access to

uninsured individuals following approval by the United States Food

and Drug Administration;

(G9) a plan to train and credential medical providers

providers to administer ibogaine treatment according to developed clinical

clinical standards; and

(H10) financial disclosures that verify the

applicant'sconsortium's capacity to fully match state funding. with funds

(c) The commission shall:

(1) make available the application required under this

section; and

(2) announce a period of not less than 90 days during

which applicants may submit an application under this chapter.

received from non-state sources.

Sec. 491.005054. COMMISSION SELECTION COMMITTEE. (a) The commission, in the

shall create a selection committee and select the number of

members. The committee must be composed of:

(1) subject matter experts;

(2) philanthropic partners; and

(3) legislative designees.

(b) The selection committee shall review applications,

communicate supplemental inquiries to applicants, and recommend to

commission's sole discretion, shall select a consortium

established in accordance with Section 491.051 for the purpose of

conducting ibogaine drug development clinical trials under this

subchapter.

Sec. 491.055. CONTRACT WITH LEAD INSTITUTION. (a) As soon

as practicable after selecting a consortium to conduct ibogaine

drug development clinical trials under Section 491.054, the

the commission theshall bestenter applicantsinto toan conductinteragency thecontract, drugas developmentprovided by

Chapter 771, Government Code, with the lead institution of higher

education of the selected consortium to provide funding to

implement the consortium's proposed ibogaine drug development

clinical trials.

(c) The commission shall consider the recommendations of

(b) The interagency contract described by Subsection (a)

must specify:

(1) the goals and objectives of the proposed ibogaine

drug development clinical trials;

(2) the proposed budget;

the selection committee in selecting(3) the applicanttimeline tofor conductcompleting the proposed

objectives;

(4) the for-profit, nonprofit, or public benefit

corporate entities collaborating with the consortium in the drug

development clinical trials under this subchapter;

(5) the percentage of the revenue arising from the

ibogaine drug development trial.clinical trials to be paid to the state; and

Sec. 491.006. INVESTIGATIONAL NEW DRUG APPLICATION. On

notification(6) fromany other information required by the commission that the applicant was selected to.

conduct the ibogaine drug development trial, the applicant shall,

as(c) As soon as practicable: after entering into an

interagency contract under Subsection (a), the commission shall

report the existence of the contract to the legislature.

(d) The commission may not disburse funds to or for a

selected consortium under the interagency contract described by

Subsection (a) until the consortium receives and the commission

verifies the receipt of matching funds from sources other than the

state.

Sec. 491.056. INVESTIGATIONAL NEW DRUG APPLICATION. On the

commission's notification that a consortium is selected to conduct

the drug development clinical trials under this subchapter, a drug

developer or hospital member of the selected consortium or the lead

institution of higher education of the consortium, as specified by

written agreement of the consortium members, shall, as soon as

practicable:

(1) submit an investigational new drug (IND)

application withto the United States Food and Drug Administration in

accordance with 21 C.F.R. Part 312; and

(2) seek a breakthrough therapy designation for

ibogaine from the United States Food and Drug Administration under

21 U.S.C. Section 356.

Sec. 491.007057. ESTABLISHMENT OF DRUG DEVELOPMENT CLINICAL TRIAL SITES. For

SITES. On approval of the applicant's investigational new drug

application by the United States Food and Drug Administration, the

commission shall, in consultation with the applicant, establish

drug development trial sites that must be equipped and staffed to

provide cardiac intensive care services to patients.

purposes of conducting a drug development clinical trial under this

subchapter, only an institution of higher education or a hospital

may serve as a trial site.

Sec. 491.008058. CONDUCTINGFUNDING; DRUGDISBURSEMENT DEVELOPMENTBY TRIALCOMMISSION. (a) As

The commission and consortium members may solicit and accept gifts,

grants, and donations of any kind received from sources other than

soonthe asstate practicablefor afterpurposes of funding drug development trialclinical sites aretrials

established under Section 491.007, the applicant shall begin a drug

development trial to administer treatment with ibogaine.

(b) The commission, in consultation with the selection

committee under Section 491.005, shall select an institutional

review board with a presence in this state to oversee and verify the

drug development trial research activity for scientific validation

and authentication under the requirements of the United States Food

and Drug Administration.

(c) The applicant shall request the designation under 21

under this subchapter.

(b) Disbursements of funds by the commission may be made

incrementally based on the completion of clearly defined objectives

as negotiated in the contract described by Section 491.055,

including verifiable documentation demonstrating the efficient

expenditure of both state and matching funds.

Sec. 491.059. REPORTING REQUIREMENTS. (a) A consortium

U.S.C.selected Sectionto 356conduct during theibogaine drug development trialclinical iftrials theshall

ibogaine treatment is demonstrating efficacy.

Sec. 491.009. FUNDING. (a) The commission may use money

appropriated to the commission and money received as a gift, grant,

or donation to pay for a grant under this chapter. The commission

may solicit and accept gifts, grants, and donations of any kind and

from any source for purposes of this section.

quarterly prepare and submit to the commission:

(b1) Ana applicantreport selectedon tothe performprogress aof the drug development

clinical trials conducted under this subchapter; and

(2) a financial status report, including information

to verify expenditures of state funds and required matching funds.

(b) The commission shall submit a report to the legislature

on the progress of the drug development clinical trials conducted

trial under this chaptersubchapter shallnot contributelater towardthan theDecember cost1 of each year.

developing the ibogaine treatment an amount of money that is at

least equal to the amount of money that the applicant received in

the form of a grant from the commission.

SECTION 2. If before implementing any provision of this Act

a state agency determines that a waiver or authorization from a

Sec. 491.060. ALLOCATION OF REVENUE ATTRIBUTABLE TO

INTELLECTUAL PROPERTY AND OTHER RIGHTS. (a) The revenue

attributable to all intellectual property rights and other

commercial rights arising from drug development clinical trials

conducted by a consortium under this subchapter during the period

for which the trials are funded and any following period of

commercialization shall be allocated as follows:

(1) not less than 20 percent to the state as specified

in the contract under Section 491.055; and

(2) the remainder to the members of the consortium in

the amounts specified by written agreement of the members.

(b) For purposes of this section, intellectual property

rights and other commercial rights arising from the drug

development clinical trials conducted under this subchapter

include any of the following as related to the trials:

(1) intellectual property, technology, and

inventions;

(2) patents, trademarks, and licenses;

(3) proprietary and confidential information;

(4) trade secrets, data, and databases;

(5) tools, methods, and processes;

(6) treatment models or techniques;

(7) administration protocols; and

(8) works of authorship.

Sec. 491.061. USE OF STATE REVENUE. (a) The comptroller

shall deposit the revenue received under Section 491.060 to the

credit of the general revenue fund.

(b) Of the amount deposited under Subsection (a), 25 percent

may be appropriated only to programs that assist veterans in this

state.

(c) The comptroller shall develop accounting procedures for

the purpose of implementing this section.

SUBCHAPTER C. IBOGAINE TREATMENT ADMINISTRATION

Sec. 491.101. APPLICABILITY. This subchapter applies only

if ibogaine is approved by the United States Food and Drug

Administration to treat a medical condition.

Sec. 491.102. MEDICAL SUPERVISION. A physician licensed

under Subtitle B, Title 3, Occupations Code, who has prescribed

ibogaine for a patient shall supervise the administration of

ibogaine at a hospital or other licensed health care facility to

ensure the patient's safety while the patient is under the

influence of ibogaine.

Sec. 491.103. ADMINISTRATION UNDER FEDERAL LAW. This

subchapter does not preclude a physician from administering

ibogaine in accordance with federal law.

SECTION 2. (a) If before implementing any provision of this

Act a state agency determines that a waiver or authorization from a

federal agency is necessary for implementation of that provision,

the agency affected by the provision shall request the waiver or

authorization and may delay implementing that provision until the

waiver or authorization is granted.

(b) The Health and Human Services Commission shall begin

accepting proposals from consortiums under Chapter 491, Health and

Safety Code, as added by this Act, not later than the 60th day after

the effective date of this Act.

SECTION 3. This Act takes effect immediately if it receives

3 unchanged paragraphs

a vote of two-thirds of all the members elected to each house, as

provided by Section 39, Article III, Texas Constitution. If this

Act does not receive the vote necessary for immediate effect, this

Act takes effect September 1, 2025.

______________________________

______________________________

President of the Senate

Speaker of the House

I hereby certify that S.B. No. 2308 passed the Senate on

April 30, 2025, by the following vote: Yeas 26, Nays 5;

May 15, 2025, Senate refused to concur in House amendments and

requested appointment of Conference Committee; May 20, 2025, House

granted request of the Senate; May 31, 2025, Senate adopted

Conference Committee Report by the following vote: Yeas 27,

Nays 4.

______________________________

Secretary of the Senate

I hereby certify that S.B. No. 2308 passed the House, with

amendments, on May 13, 2025, by the following vote: Yeas 138,

Nays 2, two present not voting; May 20, 2025, House granted request

of the Senate for appointment of Conference Committee;

June 1, 2025, House adopted Conference Committee Report by the

following vote: Yeas 134, Nays 4, one present not voting.

______________________________

Chief Clerk of the House

Approved:

______________________________

Date

______________________________

Governor

Back to the full text